Imara M&A

● ● ELVN-001: Despite Great Advances, a Significant Need Remains for Better Treatment Options for Chronic Myeloid Leukemia Challenges with Current Standard of Care Approximately 1 in 5 patients switch therapy within the first year and ~40% of patients switch in the first 5 years (1L & 2L) Growing 3L+ patient population (>25% of CP-CML) with limited treatment options Except for asciminib, approved TKIs have poor kinase selectivity, resulting in tolerability issues that impact efficacy • Comorbidities, restrictions with concomitant medications, and specific administration requirements impede long-term patient adherence • Fewer than 10% of patients successfully achieve sustained treatment-free remission (TFR) Majority of HCPs (77%) indicated need for more effective, safe, and tolerable agents in CML Switching Dynamics Demonstrate Unmet Need Rationale for Treatment Switching Intolerance ~30% Other ~5% Lack of response ~30% Loss of response (eg, >2 years post-initiation) ~35% In the US and EU3, majority of treatment switches across lines of therapy and TKIs are driven by intolerance or initial lack of molecular response (~60% combined) TKI = Tyrosine kinase inhibitors, HCP= Healthcare professional References: HCP Qualitative & Quantitative Interviews (ClearView); Hochhaus A et al. ASH 2015; Hochhaus A et al. Leukemia. 2017; 31(7):1525-1531; Osorio S et al. Ann Hematol. 2018; 97(11):2089-2098; Rea et al. Blood. 2021; blood.2020009984; Baccarani M and Gale RP. Leukemia. 2021; 35:2199-2204; Icsluig® (ponatinib) USPI; Sprycel® (dasatinib) USPI; Tasigna (nilotinib) USPI.; Bosulife (bosutinib) USPI 9

View entire presentation